Pursuits
Mylan $23 Million Chairman Shows Looming Teva Culture Clash
This article is for subscribers only.
Mylan NV Executive Chairman Robert Coury made $22.7 million, including $1 million for his personal use of the drugmaker’s two corporate jets, in 2012 and 2013. At Israeli rival Teva, shareholders in 2012 balked at raising the chairman’s salary to $900,000 a year.
The contrast highlights the sharp differences that separate the two companies as Teva Pharmaceutical Industries Ltd. pursues its unsolicited $40.1 billion offer for Mylan, a competing producer of generic drugs based in Pennsylvania.